Merck, in a statement, said its negotiations to buy SpringWorks are ongoing, confirming an earlier report from Reuters. The Darmstadt, Germany-based company said that no legally binding agreement ...
2d
Asian News International on MSNMerck Foundation CEO Together with First Ladies of Africa Mark International Women's Day 2025 Through Their 'More Than a Mother' CampaignIndia], March 11: Merck Foundation, the philanthropic arm of Merck KGaA Germany, together with First Ladies of Africa and ...
FRANKFURT, March 6 (Xinhua) -- German science and technology giant Merck Group reported a return to growth in 2024, with net sales rising 0.8 percent to 21.16 billion euros (22.8 billion U.S. dollars) ...
Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics On Monday, Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions ...
Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.
3d
Clinical Trials Arena on MSNMerck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
Merck Germany also confirmed that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met.
Germany’s Merck MRK-2.82%decrease; red down pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX-3.57%decrease; red down pointing ...
Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results